Search results for "PML"
showing 4 items of 14 documents
An Experimental Comparison between an Ironless and a Traditional Permanent Magnet Linear Generator for Wave Energy Conversion
2022
Permanent Magnet Linear Generators (PMLGs) are currently being studied for sea wave energy harvesting. Typically, a PMLG consists of an iron-made armature and a moving translator. The permanent magnets adoption produces parasitic effects, such as cogging force, and the machine weight increment. A solution could be the adoption of an ironless configuration, accepting a power density reduction. This paper investigates the use of ironless PMLGs in sea wave energy conversion systems by an experimental comparative analysis between an iron PMLG prototype and an ironless PMLG prototype, which share the same geometry. The main electrical and mechanical parameters (resistance, mass, and magnetic fie…
Synthesis, X-ray Structure Determination, and Comprehensive Photochemical Characterization of (Trifluoromethyl)diazirine-Containing TRPML1 Ligands
2021
Potential (trifluoromethyl)diazirine-based TRPML1 ion channel ligands were designed and synthesized, and their structures were determined by single-crystal X-ray diffraction analysis. Photoactivation studies via 19F NMR spectroscopy and HPLC-MS analysis revealed distinct kinetical characteristics in selected solvents and favorable photochemical properties in an aqueous buffer. These photoactivatable TRPML activators represent useful and valuable tools for TRPML photoaffinity labeling combined with mass spectrometry.
Immunological Markers for PML Prediction in MS Patients Treated with Natalizumab
2015
International audience; Natalizumab (NTZ), a monoclonal antibody recognizing the alpha4 integrin chain, has been approved for the treatment of active multiple sclerosis, but expose to the onset of a rare side effect, progressive multifocal leukoencephalopathy (PML). Estimating the individual risk of PML in NTZ-treated patients is a major challenge, and therapeutic strategies are mainly guided by the overall PML risk assessed by identified risk factors: JC virus (JCV) seropositivity, treatment duration (with peak incidence after 24 months), and the previous use of immunosuppressive therapies. Given that this stratification does not yet allow a precise individual prediction of PML, other pred…
Natalizumab therapy of multiple sclerosis: recommendations of the Multiple Sclerosis Study Group-Italian Neurological Society
2011
Three years after the introduction of natalizumab (NA) therapy for the second line treatment of relapsing-remitting multiple sclerosis (MS), Italian MS centers critically reviewed the scientific literature and their own clinical experience. Natalizumab was shown to be highly efficacious in the treatment of MS. However, the risk of progressive multifocal leukoencephalopathy was confirmed and defined better. This article summarizes the MS-SIN Study Group recommendations on the use of NA in MS, with particular reference to the appropriate selection and monitoring of patients as well as to the management of adverse events.